vimarsana.com

நல்லிணக்கம் இடையில் நிகர இழப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SenesTech Announces 2021 Second Quarter Financial and Operational Results

SenesTech Announces 2021 Second Quarter Financial and Operational Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

SenesTech Announces 2021 Second Quarter Financial and Operational Results

SenesTech Announces 2021 Second Quarter Financial and Operational Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

SenesTech : Announces 2021 Second Quarter Financial and Operational Results (Form 8-K)

SenesTech : Announces 2021 Second Quarter Financial and Operational Results (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

SenesTech Announces 2021 First Quarter Financial and Operational Results

SenesTech Announces 2021 First Quarter Financial and Operational Results Revenues Up 138 Percent from the First Quarter in 2020 News provided by Share this article Share this article PHOENIX, May 13, 2021 /PRNewswire/ SenesTech, Inc. (NASDAQ: SNES), (www.senestech.com) the rodent fertility control experts and inventors of the first and only registered rat contraceptive, ContraPest ® announced today revenues for the first quarter in 2021 were up 138 percent from the same period a year ago while operating expenses have been reduced by 20 percent. During the past year, SenesTech has transitioned from a science-based research company to a solutions-based, environmentally responsible commercial company providing a new and proven tool to pest control management for the 21

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.